Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Technical Presentation (July 2017)

13 slides from Reata Pharmaceuticals's technical presentation, Jul 24, 2017

  1. Slide 1: CARDINAL Phase 2 Results and Update

    CARDINAL PHASE 2 RESULTS AND UPDATE Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement

  3. Slide 3: Overview of Alport Syndrome

    Overview of Alport Syndrome Alport Syndrome Pathophysiology Type IV collagen mutations cause defects in the glomerular basement membrane (GBM) Patients present with hematuria and then develop proteinuria and deterioration of kidney function, leading to end-stage renal disease (ESRD) Deafness and ocu

  4. Slide 4: CARDINAL Phase 2 Trial Design

    CARDINAL Phase 2 Trial Design Open-label trial designed with input from international key opinion leaders and the Alport Syndrome Foundation Key eligibility criteria include: Genetically-confirmed diagnosis Age range from 12 to 60 years old Broad range of kidney function (eGFR between 30-90 mL/min/1

  5. Slide 5: Interim Results from CARDINAL Phase 2 Demonstrate Significant, Time-Dependent Effect on eGFR

    Interim Results from CARDINAL Phase 2 Demonstrate Significant, Time-Dependent Effect on eGFR Change from Baseline in eGFR (mL/min/1.73 m2) in All Patients Week 1 Week 4 Week 8 Week 12 N* 23 19 13 8 Mean 4.0 6.9 8.5 12.7 95% Confidence Interval 2.5 – 5.6 3.7 – 10.2 4.4 – 12.5 7.9 – 17.5 p-value < 0.0

  6. Slide 6: Results Consistent with Previous Trials in Diabetic CKD

    CARDINAL Results Consistent with Previous Trials in Diabetic CKD CARDINAL Phase 2 efficacy data to date are consistent with results from trials in diabetic CKD that enrolled over 2,600 patients Efficacy data to date is similar to BEAM (primarily Stage 3 diabetic CKD) and better than BEACON (Stage 4

  7. Slide 7: Summary of Available Phase 2 CARDINAL Safety Data

    Summary of Available Phase 2 CARDINAL Safety Data No premature discontinuations No serious adverse events No consistent AEs, except muscle spasms, which were observed in diabetic CKD patients and not associated with muscle injury AEs to date have generally been mild to moderate in intensity No safet

  8. Slide 8: CARDINAL Phase 3 Trial Design

    CARDINAL Phase 3 Trial Phase 3 portion of the trial is designed to support regulatory approval for Alport syndrome Design incorporates insights from all prior CKD studies including dose-response, predictors of response, and other design elements Double-blind, placebo-controlled with 1:1 randomizatio

  9. Slide 9: Statistical Design Leverages Phase 2 and Prior Diabetic CKD Data

    Statistical Design Leverages Phase 2 and Prior Diabetic CKD Data Primary and key secondary endpoints are powered as follows: Primary endpoint has at least 80% power to detect eGFR change of 3.1 mL/min/1.73 m2 Key secondary endpoint powered to detect eGFR change of 2.2 mL/min/1.73 m2 BEAM and BEACON

  10. Slide 10: CARDINAL Phase 3 Is Optimized

    CARDINAL is Optimized Phase 3 has multiple layers of conservatism CARDINAL sample size is anticipated to be 66% greater than BEAM Baseline eGFR expected to be higher than BEAM Modeling assumes no placebo decline, which is unlikely Study could be successful with effect size 60% less than CARDINAL Pha

  11. Slide 11: Potential Bard Alport Syndrome Target Product Profile

    Potential Bard Alport Syndrome Target Product Profile Bard has potential to become the first treatment approved for Alport syndrome No therapies are approved for this deadly, chronic, orphan disease Off-label use of RAAS agents has minimal impact of slowing disease progression Bard has a novel, pote

  12. Slide 12: Bard Targets Common Phenotype Shared by Many Types of Chronic Kidney Disease

    Bard Targets Common Phenotype Shared by Many Types of Chronic Kidney Disease Bard targets inflammatory processes that degrade renal function in many forms of CKD CARDINAL results to date and existing body of data encourage study of bard in additional, rare renal diseases Potential additional target

  13. Slide 13: Slide 13

Reata Pharmaceuticals — Technical Presentation (July 2017) on 6ix